GSK Yanks Bid To Combine Tykerb With Roche's Herceptin
GlaxoSmithKline PLC has withdrawn its supplemental application to the U.S. Food and Drug Administration seeking approval to combine its breast cancer drug Tykerb with Roche Holding AG's rival drug Herceptin because...To view the full article, register now.
Already a subscriber? Click here to view full article